Galapagos NV Earnings Recaps
Q3 2025
Nov 6, 2025
Galapagos reported a challenging third quarter of 2025, marked by the decision to wind down its cell therapy business amid unsuccessful acquisition discussions, while refocusing on core development efforts and potential business opportunities.
Key takeaways
- The Board has unanimously agreed to wind down the cell therapy division, impacting approximately 365 employees across several global locations.
- An extensive strategic review yielded no viable proposals for the cell therapy business, prompting the decision to seek alternative paths for value realization.
- The TYK2 program continues to progress, with Phase III enabling studies fully enrolled and data expected by early 2026.
- New board appointments were made to strengthen governance and support the transition towards a focused business development strategy.